CY1117302T1 - Αντισωματα αντι-mif - Google Patents

Αντισωματα αντι-mif

Info

Publication number
CY1117302T1
CY1117302T1 CY20151100250T CY151100250T CY1117302T1 CY 1117302 T1 CY1117302 T1 CY 1117302T1 CY 20151100250 T CY20151100250 T CY 20151100250T CY 151100250 T CY151100250 T CY 151100250T CY 1117302 T1 CY1117302 T1 CY 1117302T1
Authority
CY
Cyprus
Prior art keywords
mif
antibodies
relates
antigen
binding fragments
Prior art date
Application number
CY20151100250T
Other languages
English (en)
Inventor
Randolf Kerschbaumer
Friedrich Scheiflinger
Manfred Rieger
Michael Thiele
C Geert Mudde
Juergen Muellberg
Rene Hoet
Original Assignee
Baxter International Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter International Inc. filed Critical Baxter International Inc.
Publication of CY1117302T1 publication Critical patent/CY1117302T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται σε μονοκλωνικά αντισώματα και τμήματα αυτών δέσμευσης με αντιγόνο που δεσμεύονται ειδικά με το C-άκρο ή την κεντρική περιοχή του παράγοντα αναστολής της μετανάστευσης μακροφάγων (MIF). Τα εν λόγω αντισώματα αντι-MIF και τα τμήματα αυτών δέσμευσης με αντιγόνο επιπλέον αναστέλλουν τη βιολογική λειτουργία του ανθρωπίνου MIF. Η αίτηση αναφέρεται επίσης σε απομονωμένες ανοσοσφαιρίνες βαριάς και ελαφριάς αλυσίδας που προέρχονται από αντισώματα αντι-MIF και μόρια νουκλεϊνικών οξέων που κωδικοποιούν τέτοιες ανοσοσφαιρίνες. Η παρούσα αίτηση αναφέρεται επίσης σε μια μέθοδο ταυτοποίησης αντισωμάτων αντι-MIF, σε φαρμακευτικές συνθέσεις που περιλαμβάνουν τα εν λόγω αντισώματα και μια μέθοδο χρήσης των εν λόγω αντισωμάτων και συνθέσεων για τη θεραπευτική αγωγή διαταραχών σχετικών με τον MIF.
CY20151100250T 2008-01-04 2015-03-13 Αντισωματα αντι-mif CY1117302T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1898808P 2008-01-04 2008-01-04
US9468508P 2008-09-05 2008-09-05
EP08869976.4A EP2231707B1 (en) 2008-01-04 2008-12-30 Anti mif antibodies

Publications (1)

Publication Number Publication Date
CY1117302T1 true CY1117302T1 (el) 2017-04-26

Family

ID=40535633

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20151100250T CY1117302T1 (el) 2008-01-04 2015-03-13 Αντισωματα αντι-mif

Country Status (23)

Country Link
US (3) US20090220521A1 (el)
EP (4) EP2231707B1 (el)
JP (1) JP5502752B2 (el)
KR (2) KR101654678B1 (el)
CN (2) CN103724430B (el)
AU (1) AU2008346517B2 (el)
BR (1) BRPI0821682A2 (el)
CA (1) CA2711029A1 (el)
CY (1) CY1117302T1 (el)
DK (1) DK2231707T3 (el)
ES (3) ES2623653T3 (el)
HK (1) HK1147762A1 (el)
HR (1) HRP20150224T1 (el)
IL (1) IL206715A (el)
MX (1) MX2010007406A (el)
NZ (3) NZ611117A (el)
PL (2) PL3118223T3 (el)
PT (1) PT2231707E (el)
RS (1) RS53906B1 (el)
RU (2) RU2509777C2 (el)
SI (1) SI2231707T1 (el)
WO (1) WO2009086920A1 (el)
ZA (1) ZA201004973B (el)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2231707B1 (en) * 2008-01-04 2014-12-24 Baxter International Inc. Anti mif antibodies
US9238689B2 (en) 2011-07-15 2016-01-19 Morpho Sys AG Antibodies that are cross-reactive for macrophage migration inhibitory factor (MIF) and D-dopachrome tautomerase (D-DT)
AU2012320597C1 (en) 2011-10-07 2015-10-15 Baxalta GmbH oxMIF as a diagnostic marker
JP2014530361A (ja) * 2011-10-07 2014-11-17 バクスター・ヘルスケヤー・ソシエテ・アノニムBaxter Healthcare SA Cho−mif遺伝子およびタンパク質の特性評価およびその使用
AU2013202693B2 (en) * 2012-04-16 2015-01-22 Baxalta GmbH Combination Therapy of Anti-MIF Antibodies and Chemotherapeutics
AU2013203957B9 (en) * 2012-04-16 2015-10-15 Baxalta GmbH Combination Therapy of Anti-MIF Antibodies and Glucocorticoids
JP2015523572A (ja) 2012-07-10 2015-08-13 バクスター・ヘルスケヤー・ソシエテ・アノニムBaxter Healthcare SA 抗mif免疫組織化学法
EP2929348B1 (en) * 2012-12-07 2017-05-10 Baxalta GmbH Anti-mif antibody cell migration assay
US10613100B2 (en) * 2014-01-03 2020-04-07 Baxalta Incorporated Anti-MIF immunohistochemistry
WO2016026956A1 (en) 2014-08-22 2016-02-25 Baxalta GmbH Detection of cho-mif contaminations
EP3277718B1 (en) 2015-03-31 2021-03-24 Baxalta GmbH Dosage regimen for anti-mif antibodies
EP3298039A1 (en) 2015-05-18 2018-03-28 Baxalta GmbH Anti-mif antibodies in the treatment of cancers containing mutant tp53 and/or mutant ras
US11098113B2 (en) 2016-09-15 2021-08-24 Vib Vzw Immunoglobulin single variable domains directed against macrophage migration inhibitory factor
CN109868311B (zh) * 2017-12-01 2023-10-20 上海市精神卫生中心 Mif及其预测二代抗精神病药物诱导的代谢不良反应的应用
JP2021526820A (ja) * 2018-06-07 2021-10-11 オンコワン・リサーチ・アンド・ディベロップメント・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 癌治療のための抗oxMIF/抗CD3抗体
EP3757252B1 (en) 2019-06-28 2022-03-30 Walter Ag A coated cutting tool
CN115943160A (zh) 2019-12-06 2023-04-07 翁科奥内研发有限责任公司 抗oxMIF/抗CD3双特异性抗体构建体
EP4222170B1 (en) 2020-10-02 2024-03-20 OncoOne Research & Development GmbH Improved anti-oxmif antibodies with reduced aggregation potential and reduced hydrophobicity
AU2022218320A1 (en) 2021-02-03 2023-07-27 Oncoone Research & Development Gmbh ANTI-oxMIF RADIOIMMUNOCONJUGATE
WO2023031397A1 (en) 2021-09-03 2023-03-09 Oncoone Research & Development Gmbh IMPROVED Fc SILENCED ANTI-oxMIF ANTIBODIES WITH REDUCED AGGREGATION POTENTIAL AND REDUCED HYDROPHOBICITY
WO2023133361A2 (en) * 2022-01-10 2023-07-13 Phenomic Ai Anti-cthrc1 fusion proteins and methods of using the same
CN114573693A (zh) * 2022-04-25 2022-06-03 中国人民解放军陆军军医大学 一种听觉发育中免疫调节分子mif抗体制备方法
CN115814069B (zh) * 2022-10-31 2023-07-21 四川大学华西医院 Mif基因敲除的肿瘤细胞在制备肿瘤疫苗中的用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6774227B1 (en) * 1993-05-17 2004-08-10 Cytokine Pharmasciences, Inc. Therapeutic uses of factors which inhibit or neutralize MIF activity
US6080407A (en) * 1993-05-17 2000-06-27 The Picower Institute For Medical Research Diagnostic assays for MIF
JPH0977799A (ja) * 1995-09-13 1997-03-25 Sapporo Immuno Diagnostic Lab:Kk ヒト−マクロファージ遊走阻止因子(ヒト−mif)に対するモノクローナル抗体および該抗体を産生するハイブリドーマ
DK1156823T3 (da) * 1999-02-12 2009-01-19 Scripps Research Inst Fremgangsmåder til behandling af tumorer og metastaser ved anvendelse af en kombination af anti-angiogene terapier og immunoterapier
US20030235584A1 (en) * 2000-02-28 2003-12-25 Kloetzer William S. Method for preparing anti-MIF antibodies
AR045563A1 (es) * 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
CN100457895C (zh) * 2006-05-24 2009-02-04 中国科学院生物物理研究所 鼠抗人巨噬细胞迁移抑制因子单克隆抗体及其应用
EP2231707B1 (en) * 2008-01-04 2014-12-24 Baxter International Inc. Anti mif antibodies

Also Published As

Publication number Publication date
EP2754671A2 (en) 2014-07-16
RU2509777C2 (ru) 2014-03-20
RU2010132647A (ru) 2012-02-10
PL3118223T3 (pl) 2021-04-06
ZA201004973B (en) 2011-03-30
DK2231707T3 (en) 2015-03-02
SI2231707T1 (sl) 2015-04-30
CN101983207B (zh) 2016-01-20
MX2010007406A (es) 2010-10-05
BRPI0821682A2 (pt) 2015-06-16
EP2754671A3 (en) 2015-07-08
NZ596409A (en) 2013-05-31
AU2008346517A1 (en) 2009-07-16
EP2231707B1 (en) 2014-12-24
CN101983207A (zh) 2011-03-02
ES2791333T3 (es) 2020-11-03
RS53906B1 (en) 2015-08-31
KR101654678B1 (ko) 2016-09-08
IL206715A0 (en) 2010-12-30
PL2231707T3 (pl) 2015-05-29
HRP20150224T1 (en) 2015-06-05
EP3118223B8 (en) 2020-04-15
IL206715A (en) 2015-06-30
US20090220521A1 (en) 2009-09-03
ES2623653T3 (es) 2017-07-11
CN103724430A (zh) 2014-04-16
CN103724430B (zh) 2016-09-21
KR20100102197A (ko) 2010-09-20
EP2231707A1 (en) 2010-09-29
EP3118223A1 (en) 2017-01-18
US20150023978A1 (en) 2015-01-22
NZ586600A (en) 2012-05-25
JP5502752B2 (ja) 2014-05-28
US8668909B2 (en) 2014-03-11
JP2011510616A (ja) 2011-04-07
KR20160105943A (ko) 2016-09-07
EP2754671B1 (en) 2016-12-21
AU2008346517B2 (en) 2013-12-05
EP3118223B1 (en) 2020-02-19
NZ611117A (en) 2014-10-31
PT2231707E (pt) 2015-03-25
US20100260768A1 (en) 2010-10-14
EP2548890A1 (en) 2013-01-23
RU2013153592A (ru) 2015-06-10
WO2009086920A1 (en) 2009-07-16
ES2531629T3 (es) 2015-03-18
CA2711029A1 (en) 2009-07-16
HK1147762A1 (en) 2011-08-19

Similar Documents

Publication Publication Date Title
CY1117302T1 (el) Αντισωματα αντι-mif
CY1120665T1 (el) Ανθρωποποιημενα αντισωματα anti-cxcr5, παραγωγα αυτων και χρησεις τους
CY1120065T1 (el) Ανθρωπινα αντισωματα για ton erbb 2
CY1118845T1 (el) Πρωτεϊνες συνδεσης αντιγονου υποδοχεα α il-17
CY1122476T1 (el) Βελτιστοποιημενα μονοκλωνικα αντισωματα εναντι του αναστολεα της οδου του ιστικου παραγοντα (τfρι)
CY1121538T1 (el) Μονοκλωνικα αντισωματα εναντι του αναστολεα του μονοπατιου ιστικου παραγοντα (tfpi)
CY1119454T1 (el) Αντισωματα εναντι cd38 για τη θεραπεια του πολλαπλου μυελωματος
CY1124747T1 (el) Ανθρωπινα αντισωματα σε pd-1
CY1122366T1 (el) Θεραπεια της οξειας λεμφοβλαστικης λευχαιμιας
CY1120471T1 (el) Αντισωματα κατα του cd70
CY1120626T1 (el) Αντισωματα και αλλα μορια που δεσμευουν β7-η1 και pd-1
CO6351802A2 (es) Anticuerpos para ccr2
CY1113089T1 (el) Ανθρωπινα μονοκλωνικα αντισωματα σε ειδικο προστατικο μεμβρανικο αντιγονο (psma)
CY1115572T1 (el) Αντι cxcr4 αντισωματα και χρηση αυτων για τη θεραπεια καρκινου
EA201291243A1 (ru) Антитела против респираторно-синцитиального вируса (рсв) и способы их применения
BR112012003064B8 (pt) anticorpo ou fragmento de ligação de antígeno do mesmo, combinação que os compreende, método de detecção de infecção por rsv, moléculas de ácido nucléico, e método de produção de um anticorpo ou fragmento de ligação de antígeno do mesmo
CY1114872T1 (el) Συνθεσεις και μεθοδοι χρησης αντισωματων εναντι της σκληροστεϊνης
WO2008079246A3 (en) Cd44 antibodies
CY1118665T1 (el) Συνθεσεις και μεθοδοι για θεραπεια διαταραχων χρησης αλκοολης, πονου και αλλων ασθενειων
CY1123781T1 (el) Anti-tnf αλφα-αντισωματα και λειτουργικα θραυσματα αυτων
UA117364C2 (uk) Похідні аматоксину
CY1119890T1 (el) Θεραπευτικη αγωγη ογκων χρησιμοποιωντας ειδικο αντισωμα αντι-l1
BR112019010595A2 (pt) anticorpo ou fragmento de ligação ao antígeno do mesmo, combinação de moléculas de ácido nucleico isoladas, composição farmacêutica, kit, e, método para selecionar um composto.
EA202091054A1 (ru) Слитые молекулы на основе антитела против pd-l1 и ил-7
CY1118046T1 (el) Πρωτεϊνες δεσμευσης με αντιγονο ειδικες για το συστατικο ρ αμυλοειδους ορου